Document is current
Any future updates will be listed below
-
Authors
van Werkhoven, Cornelis H. http://orcid.org/0000-0002-0626-4635
Ducher, Annie
Berkell, Matilda http://orcid.org/0000-0002-7096-7896
Mysara, Mohamed http://orcid.org/0000-0001-5746-4330
Lammens, Christine
Torre-Cisneros, Julian http://orcid.org/0000-0003-1529-6302
Rodríguez-Baño, Jesús http://orcid.org/0000-0001-6732-9001
Herghea, Delia
Cornely, Oliver A. http://orcid.org/0000-0001-9599-3137
Biehl, Lena M.
Bernard, Louis
Dominguez-Luzon, M. Angeles
Maraki, Sofia http://orcid.org/0000-0003-0945-1732
Barraud, Olivier http://orcid.org/0000-0003-2015-9206
Nica, Maria
Jazmati, Nathalie
Sablier-Gallis, Frederique
de Gunzburg, Jean http://orcid.org/0000-0001-8049-9283
Mentré, France
Malhotra-Kumar, Surbhi http://orcid.org/0000-0001-8699-8905
Bonten, Marc J. M.
Vehreschild, Maria J. G. T. http://orcid.org/0000-0003-0446-3224
,
Engbers, Annemarie M. S.
de Regt, Marieke J. A.
Goossens, Herman
Xavier, Basil Britto
Bouverne, Marie-Noelle
Monsieurs, Pieter
Merle, Uta
Stallmach, Andreas
Rupp, Jan
Bogner, Johannes
Lübbert, Christoph
Silling, Gerda
Witzke, Oliver
Gikas, Achilleas
Daikos, George
Tsiodras, Sotirios
Skoutelis, Athanasios
Sambatakou, Helen
Pujol, Miquel
Aguado, Jose M.
Bouza, Emilio
Cobo, Javier
Almirante, Benito
Florescu, Simin A.
Vata, Andrei
Hristea, Adriana
Lupse, Mihaela
Postil, Deborah
Molina, Jean-Michel
De Lastours, Victoire
Guimard, Thomas
Talarmin, Jean-Philippe
Duval, Xavier
Launay, Odile
- License Information
-
More Information
Article History
Received: 11 June 2020
Accepted: 3 March 2021
First Online: 14 April 2021
Competing interests
: C.Hv.W. received speaker fees from Pfizer and Merck/MSD, and non-financial research support from bioMérieux. A.D. and F.S. are employees and shareholders of Da Volterra, Paris. J.G. is a consultant and shareholder of Da Volterra. J.T.C. has received speaker and consultant fess from Pfizer, MSD, Shionogy, Menarini and research support from Pfizer. O.A.C. is supported by the German Federal Ministry of Research and Education, is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy—CECAD, EXC 2030—390661388 and has received research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen, Medicines Company, Melinta, Merck/MSD, Octapharma, Pfizer, Scynexis, is a consultant to Actelion, Allecra, Amplyx, Astellas, Basilea, Biosys, Cidara, Da Volterra, Entasis, F2G, Gilead, Matinas, MedPace, Menarini, Merck/MSD, Mylan, Nabriva, Noxxon, Octapharma, Paratek, Pfizer, PSI, Roche Diagnostics, Scynexis, and Shionogi, and received lecture honoraria from Al-Jazeera Pharmaceuticals, Astellas, Basilea, Gilead, Grupo Biotoscana, Merck/MSD and Pfizer. L.M.B. has received lecture honoraria from Astellas and Merck/MSD, and travel grants from 3M and Gilead. OB received speaker fees and/or travel grants from Pfizer, MSD, Roche and Sanofi and has been a consultant to bioMérieux and Mylan. F.M. is a consultant for Da Volterra, IPSEN, Servier and received research grants from Da Volterra, Sanofi and Servier. MJGTV has received research grants from 3M, Astellas Pharma, Da Volterra, Gilead Sciences, Glycom, MaaT Pharma, Merck/MSD, Organobalance, Seres Therapeutics; speaker fees from Astellas Pharma, Basilea, Gilead Sciences, Merck/MSD, Organobalance, Pfizer and has been a consultant to Alb Fils Kliniken GmbH, Astellas Pharma, Bio-Mérieux, Da Volterra, Ferring, MaaT Pharma, Merck/MSD. The remaining authors declare no competing interests.
